Antipsychotics used in DPDR primarily modulate dopaminergic and serotonergic neurotransmission, targeting disrupted neural circuits associated with self-perception and reality processing. By blocking D2 and 5-HT2A receptors, these medications can help reduce the intensity of depersonalization and derealization symptoms, potentially normalizing aberrant neural signaling and providing symptomatic relief.